Inactive Instrument

Other languages Lydall, Inc.

Equities

LDL

US5508191062

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

OptimizeRx : Set to Join S&P SmallCap 600; Stock Rises 11% After Hours	30/21/30
Lydall : Merger Partner Unifrax to Issue $1.2 Billion of Senior Secured Notes	08/21/08
Lydall, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021	29/21/29
Lydall : Earnings Flash (LDL) LYDALL Posts Q2 Revenue $221.7M	29/21/29
Update: Lydall Closes 85% Higher Following $1.3 Billion Acquisition Deal With Unifrax	22/21/22
Lydall : to be Acquired by Unifrax in $1.3 Billion Deal; Shares Halted	21/21/21
Lydall : Q1 Adjusted EPS, Sales Rise	28/21/28
Lydall, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2021	28/21/28
Lydall : Earnings Flash (LDL) LYDALL Posts Q1 Revenue $227.1M, vs. Street Est of $207.3M	28/21/28
Lydall : Ups Prices for Filtration and Specialty Insulation Products	25/21/25
Lydall : Swings To Q4 Profit as Revenue Edges Higher	24/21/24
Lydall, Inc. Reports Earnings Results for the Full Year Ended December 31, 2020	24/21/24
Lydall : Earnings Flash (LDL) LYDALL Posts Q4 Revenue $210.3M, vs. Street Est of $197.1M	24/21/24
Lydall, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2020	28/20/28
Lydall, Inc. Announces Earnings Results for the Second Quarter Ended June 30, 2020	29/20/29
Lydall, Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2018; Provides Earnings Guidance for the Second Quarter and Full Year of 2018	02/18/02
Lydall, Inc. Reports Unaudited Earnings Results for the Third Quarter and Nine Months Ended of September 30, 2017; Provides Earnings Guidance for the Full Year of 2017	01/17/01
Lydall, Inc Announces Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2017; Provides Earnings Guidance for the Full Year 2017; Announces Asset Impairment Charge During the First Quarter Ended March 31, 2017	03/17/03
Pfizer : contraint de renoncer à son potentiel blockbuster bococizumab	01/16/01
Lydall, Inc. Provides Capital Expenditure Guidance for the Full Year of 2016	03/16/03

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Lydall, Inc.

Equities

LDL

US5508191062

Other languages

Filters